Changes in surrogate laboratory markers, clinical endpoints, and health- related quality of life in patients infected with the human immunodeficiency virus

Evaluation and the Health Professions

Volumn 21, Issue 2, 1998, Pages 265-281

  Chan, Kitty S ^a,b   Revicki, Dennis A ^a  

^a Center for Health Outcomes Research

^b Center for Health Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DATA ANALYSIS; DEMOGRAPHY; DISEASE COURSE; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PROGNOSIS; QUALITY OF LIFE; STATISTICAL ANALYSIS; SURVIVAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; FEMALE; HEALTH SURVEYS; HIV INFECTIONS; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; SURVIVAL ANALYSIS;

EID: 0031959811     PISSN: 01632787     EISSN: None     Source Type: Journal    
DOI: 10.1177/016327879802100207     Document Type: Article

References (8)

1. Bozzette, S. A., Hays, R. D., Berry, S. H., & Kanouse, D. E. (1994). A perceived health index for use in persons with advanced HIV disease: Derivation, reliability, and validity. Medical Care, 32, 716-731.
2. Brezinski, D., Stone, P. H., Muller, J., Tofler G. H., Davis, V., Parker, C., Hartley, L. H., & Braunwald, E. (1991). Prognostic significance of the Karnofsky Performance Status score in patients with acute myocardial infarction: Comparison with the left ventricular ejection fraction and the exercise treadmill test performance. American Heart Journal, 121, 1374-1381.
3. Burgess, A., Dayer, M., Catalan, J., Hawkins, K., & Gazzard, B. (1993). The reliability and validity of two HIV-specific health related quality of life measures. AIDS, 7, 1001-1008.
4. CAESAR Coordinating Committee. (1997). Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial. Lancet, 349, 1413-1421.
5. Cameron, D. W., Heath-Chiozzi, M., Kravcik, S., Mills, R., Potthoff, A., & Henry, D. (1996a, January 28-February 1). Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Program and Abstracts of the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC. (Abstract No. LB6a)
6. Cameron, D. W., Heath-Chiozzi, M., Kravcik, S., Mills, R., Potthoff, A., & Henry, D. (1996b, July 7-12). For the Advanced HIV Ritonavir Study Group. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir update. Program and Abstracts of the XI International Conference on AIDS, Vancouver, British Columbia. (Abstract No. MoB411)
7. Center for Disease Control. (1992). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report. 41 (RR17)
8. Wu, A. W., Rubin, H. R., Mathews, W. C., Ware, J. E., Brysk, L. T., Hardy, W. D., Bozzette, S. A., Spector, S. A., & Richman, D. D. (1991). A health status questionnaire using 30 items from the Medical Outcomes Study: Preliminary validation in persons with early HIV infection. Medical Care, 29, 786-798.